Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
MetadataShow full item record
Buttery, P., & Barker, R. (2020). Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 17 (4), 1539-1562. https://doi.org/10.1007/s13311-020-00940-4
Parkinson's disease (PD) is a neurodegenerative disorder that carries large health and socio-economic burdens. Current therapies for PD areultimatelyinadequate, both in terms of symptom control and in modification of disease progression. Deep brain stimulation and infusion therapies are the current mainstay fortreatment of motor complications ofadvanced disease, but these have very significant drawbacksand offer no element of disease modification. In fact there are currently no agents that are established to modify the course of the disease in clinical use for PD.Gene and cell therapies for PD are now being trialledin the clinic. These treatments are diverse and may have a range of niches in the management of PD. They hold great promise for improved treatment of symptomsas well as possibly slowing progression of the diseasein the right patient group. Here we review the current state of the art for these therapies and look to future strategies in this fast-moving field
RAB has been supported by an NIHR Biomedical Research Award to Addenbrooke's Hospital/University of Cambridge, as well as grants from Parkinson's UK, Cure Parkinson's Trust, Rosetrees trust; CHDI, EU-FP7 programme, Michael J Fox Foundation, Evelyn Trust, NIHR i4I programme, MRC and the Wellcome trust. PCB is supported by an MRC-NIHR Clinical Academic Research Partnership Award.
Wellcome Trust (203151/Z/16/Z)
Medical Research Council (MC_PC_17230)
Embargo Lift Date
External DOI: https://doi.org/10.1007/s13311-020-00940-4
This record's URL: https://www.repository.cam.ac.uk/handle/1810/311029
All rights reserved